Heart failure in African Americans: Pathophysiology and treatment

Journal of Cardiac Failure

Volumn 9, Issue 5 SUPPL. 3, 2003, Pages

  Yancy, Clyde W ^a,b  

^a University of Texas Southwestern Medical Center ^*

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; HYDRALAZINE; ISOSORBIDE DINITRATE; METOPROLOL; MOXONIDINE; NITRIC OXIDE; NITRATE;

AFRICAN AMERICAN; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; GENOMICS; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SOCIOECONOMICS; ANIMAL; CONGESTIVE HEART FAILURE; ETHNOLOGY; FEMALE; MALE; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DISEASE PROGRESSION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; NITRATES; RISK FACTORS; TREATMENT OUTCOME;

EID: 2142747552     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1054/S1071-9164(03)00590-6     Document Type: Conference Paper

References (34)

1. American Heart Association. African-Americans and congestive diseases. Dallas, TX: American Heart Association; 1999.
2. Congestive heart failure in the United States: a new epidemic. Bethesda, MD: National Heart, Lung and Blood Institute; 1996.
3. Yancy CW. Heart failure in African Americans: a cardiovascular enigma. J Card Fail 2000;6:183-6.
4. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991;18(Suppl):II100-5.
5. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol 1987;10(Suppl 6):S135-40.
6. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction, [published erratum appears in N Engl J Med 1999;3414:298]. N Engl J Med 1999;340:609-16.
7. Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, August P. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 2000;97:3479-84.
8. Rivera MA, Echegaray M, Rankinen T, Perusse L, Rice T, Gagnon J, et al. TGF-beta(1) gene-race interactions for resting and exercise blood pressure in the HERITAGE Family Study. J Appl Physiol 2001;91:1808-13.
9. Siffert W. Molecular genetics of G proteins and atherosclerosis risk. Basic Res Cardiol 2001;96:606-11.
10. Abate NI, Mansour YH, Tuncel M, Arbique D, Chavoshan B, Kizilbash A, et al. Overweight and sympathetic overactivity in black Americans. Hypertension 2001;38:379-83.
11. Stein CM, Lang CC, Nelson R, Brown M, Wood AJ. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther 1997;62:436-43.
12. Kahn DF, Duffy SJ, Tomasian D, Holbrook M, Rescorl L, Russell J, et al. Effects of black race on forearm resistance vessel function. Hypertension 2002;40:195-201.
13. Cohn JN. ACE inhibition and vascular remodeling of resistance vessels: vascular compliance and cardiovascular implications. Heart Dis 2000; 2:S2-6.
14. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-8.
15. Cohn JN. Left ventricle and arteries: structure, function, hormones, and disease. Hypertension 2001;37(Part 2):346-9.
16. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
17. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
18. Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000;2:258-62.
19. Hernandez I, Carbonell LF, Quesada T, Fenoy FJ. Role of angiotensin II in modulating the hemodynamic effects of nitric oxide synthesis inhibition. Am J Physiol 1999;277(Pt 2):R104-11.
20. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of the Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
21. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis GS, Tristani FE, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
22. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Cardiac Failure 1999;5:178-87.
23. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
24. Teerlink JR, Massie BM. Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol 1999;84:94R-102R.
25. Andreka P, Aiyar N, Olson LC, Wei JQ, Turner MS, Webster KA, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002;105:2429-34.
26. Coats AJ. Heart Failure 99: the MOXCON story. Int J Cardiol 1999;71:109-11.
27. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, et al., for the U.S. Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65.
28. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.
29. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302.
30. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
31. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al., The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
32. Hobbs RE, Mills RM, Young JB. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs 2001; 10:935-42.
33. Ishibashi Y, Shimada T, Sakane T, Takahashi N, Sugamori T, Ohhata S, et al. Contribution of endogenous nitric oxide to basal vasomotor tone of peripheral vessels and plasma B-type natriuretic peptide levels in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1605-11.
34. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, et al., for the A-HeFT Investigators. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002;8:128-35.